Actelion Ltd - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Actelion Ltd - Product Pipeline Review - 2016', provides an overview of the Actelion Ltd's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Actelion Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Actelion Ltd - The report provides overview of Actelion Ltd including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Actelion Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Actelion Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to Buy - Evaluate Actelion Ltd's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Actelion Ltd - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Actelion Ltd's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Actelion Ltd Snapshot 7 Actelion Ltd Overview 7 Key Information 7 Key Facts 7 Actelion Ltd - Research and Development Overview 8 Key Therapeutic Areas 8 Actelion Ltd - Pipeline Review 11 Pipeline Products by Stage of Development 11 Pipeline Products - Monotherapy 12 Pipeline Products - Partnered Products 13 Partnered Products/Combination Treatment Modalities 14 Pipeline Products - Out-Licensed Products 15 Out-Licensed Products/Combination Treatment Modalities 16 Actelion Ltd - Pipeline Products Glance 17 Actelion Ltd - Late Stage Pipeline Products 17 Pre-Registration Products/Combination Treatment Modalities 17 Phase III Products/Combination Treatment Modalities 18 Actelion Ltd - Clinical Stage Pipeline Products 19 Phase II Products/Combination Treatment Modalities 19 Phase I Products/Combination Treatment Modalities 20 Actelion Ltd - Early Stage Pipeline Products 21 Preclinical Products/Combination Treatment Modalities 21 Discovery Products/Combination Treatment Modalities 22 Actelion Ltd - Drug Profiles 23 mechlorethamine hydrochloride 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 selexipag 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 cadazolid 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 macitentan 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 ponesimod 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 miglustat 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 clazosentan 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Small Molecule to Antagonize Endothelin Receptor A and Endothelin Receptor B for Essential Hypertension 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Cenerimod 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 AC-082 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 ACT-451840 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 ACT-541468 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 lucerastat 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Small Molecule 2 for Neurological Disorders 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Small Molecule for Cardiovascular Disorders 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 AC-080 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Small Molecule to Antagonize Orexin 2 Receptor for Sleep Disorders 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Small Molecule to Inhibit DNA Gyrase and Topoisomerase IV for Bacterial Infection 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Small Molecules for Hypertension 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Small Molecules to Antagonize Endothelin A Receptor for Hypertension 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Small Molecules to Inhibit DNA Ligase for Staphylococcal Infections 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Small Molecule for Cancer 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Actelion Ltd - Pipeline Analysis 51 Actelion Ltd - Pipeline Products by Target 51 Actelion Ltd - Pipeline Products by Route of Administration 53 Actelion Ltd - Pipeline Products by Molecule Type 54 Actelion Ltd - Pipeline Products by Mechanism of Action 55 Actelion Ltd - Recent Pipeline Updates 56 Actelion Ltd - Dormant Projects 65 Actelion Ltd - Discontinued Pipeline Products 66 Discontinued Pipeline Product Profiles 66 almorexant 66 selexipag 66 Actelion Ltd - Company Statement 67 Actelion Ltd - Locations And Subsidiaries 69 Head Office 69 Other Locations & Subsidiaries 69 Appendix 73 Methodology 73 Coverage 73 Secondary Research 73 Primary Research 73 Expert Panel Validation 73 Contact Us 73 Disclaimer 74
List of Tables
Actelion Ltd, Key Information 7 Actelion Ltd, Key Facts 7 Actelion Ltd - Pipeline by Indication, 2016 9 Actelion Ltd - Pipeline by Stage of Development, 2016 11 Actelion Ltd - Monotherapy Products in Pipeline, 2016 12 Actelion Ltd - Partnered Products in Pipeline, 2016 13 Actelion Ltd - Partnered Products/ Combination Treatment Modalities, 2016 14 Actelion Ltd - Out-Licensed Products in Pipeline, 2016 15 Actelion Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016 16 Actelion Ltd - Pre-Registration, 2016 17 Actelion Ltd - Phase III, 2016 18 Actelion Ltd - Phase II, 2016 19 Actelion Ltd - Phase I, 2016 20 Actelion Ltd - Preclinical, 2016 21 Actelion Ltd - Discovery, 2016 22 Actelion Ltd - Pipeline by Target, 2016 52 Actelion Ltd - Pipeline by Route of Administration, 2016 53 Actelion Ltd - Pipeline by Molecule Type, 2016 54 Actelion Ltd - Pipeline Products by Mechanism of Action, 2016 55 Actelion Ltd - Recent Pipeline Updates, 2016 56 Actelion Ltd - Dormant Developmental Projects,2016 65 Actelion Ltd - Discontinued Pipeline Products, 2016 66 Actelion Ltd, Subsidiaries 69
List of Figures
Actelion Ltd - Pipeline by Top 10 Indication, 2016 9 Actelion Ltd - Pipeline by Stage of Development, 2016 11 Actelion Ltd - Monotherapy Products in Pipeline, 2016 12 Actelion Ltd - Partnered Products in Pipeline, 2016 13 Actelion Ltd - Pipeline by Top 10 Target, 2016 51 Actelion Ltd - Pipeline by Route of Administration, 2016 53 Actelion Ltd - Pipeline by Molecule Type, 2016 54 Actelion Ltd - Pipeline Products by Top 10 Mechanism of Action, 2016 55
Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the glRead More...
Europe industrial air filtration market size is projected to reach USD 1,690.8 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing implementation in various industries such as metal, cement and food & beverages among otRead More...
Global air traffic control equipment market is projected to reach USD 4.2 billion by 2020, as per a new research report by Radiant Insights, Inc. Mounting price sensitivity among customers with introduction of low fare airlines is expected to drive tRead More...
Global agricultural films market size is anticipated to reach USD 10.5 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to raise agricultural productivity, in order to meet surplus demand by growing population iRead More...
Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likelyRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.